AltMountain

Baker Brothers Investments

New York, NY · CRD 158149
Hedge fund manager

Baker Brothers Investments is an SEC-registered investment adviser based in New York, NY that reports managing 2 hedge funds on Form ADV. It reports $28.1 billion in regulatory assets under management. Its private funds, of all types, hold $28.1 billion in gross assets. Its disclosed U.S. stock holdings returned an estimated +13.3% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +116.6% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.

Regulatory assets under management
$28.1 billionForm ADV Item 5.F
Gross assets of private funds
$28.1 billionAll private fund types, Form ADV
Hedge funds managed
22 private funds in total
Employees
60Form ADV Item 5.A
Registration
SEC-registered adviserCRD 158149
Latest Form ADV
03/27/2026Disciplinary disclosures: none reported

Estimated 13F portfolio performance

Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.

Estimated from 13F · 2026 YTD+13.3%Through Q2 2026 · S&P 500 +9.5%
Estimated from 13F · 2 years+116.6%Q3 2024 – Q2 2026
S&P 500+37.2%Same quarters, price only
13F holdings$19.9 billion83 positions, 2026-06-30
$100$158$217Q3 2024Q1 2025Q3 2025Q1 202613F est. $217S&P 500 $137
QuarterEst. 13F returnS&P 500
Q2 2026+13.5%+14.8%
Q1 2026-0.3%-4.6%
Q4 2025+18.6%+2.4%
Q3 2025+30.7%+7.8%
Q2 2025+6.4%+10.4%
Q1 2025-1.1%-4.5%
Q4 2024-3.8%+2.1%
Q3 2024+22.0%+5.4%

Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures

Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.

13F holdings as of Sep 30, 2026

The 50 largest of 79 share positions ($20,988,985,093) reported by Baker Bros. Advisors LP on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.

Share of the reported 13F portfolio, ten largest positions

  • Incyte Corp17.79%
  • Beone Medicines LTD15.40%
  • Revolution Medicines Inc10.40%
  • Kodiak Sciences Inc9.87%
  • Madrigal Pharmaceuticals Inc5.15%
  • Insmed Inc4.78%
  • Kymera Therapeutics Inc4.61%
  • Acadia Pharmaceuticals Inc4.12%
  • Grail Inc2.69%
  • Summit Therapeutics Inc2.64%
StockValue% of 13F portfolioSharesShares vs prior quarter
Incyte Corp$3,733,047,82017.79%30,762,652Unchanged
Beone Medicines LTD$3,232,104,67015.40%8,832,335+0.35%
Revolution Medicines Inc$2,183,415,89310.40%10,637,318-7.04%
Kodiak Sciences Inc$2,072,417,2079.87%21,860,941+9.75%
Madrigal Pharmaceuticals Inc$1,080,052,2995.15%2,143,131Unchanged
Insmed Inc$1,003,988,1104.78%8,796,111Unchanged
Kymera Therapeutics Inc$967,793,0834.61%8,657,242Unchanged
Acadia Pharmaceuticals Inc$864,695,0164.12%42,912,904Unchanged
Grail Inc$564,489,3942.69%4,028,614Unchanged
Summit Therapeutics Inc$554,417,1452.64%32,786,348Unchanged
Rhythm Pharmaceuticals Inc$533,630,8492.54%5,604,483Unchanged
Praxis Precision Medicines I$510,583,8542.43%1,753,198Unchanged
Abcellera Biologics Inc$481,647,1082.29%33,012,139Unchanged
Alkermes PLC$405,697,0591.93%10,012,267Unchanged
Celcuity Inc$382,951,7801.82%4,815,792-39.16%
Kiniksa Pharmaceuticals Intl$211,492,7141.01%2,834,643Unchanged
Ideaya Biosciences Inc$192,485,3530.92%5,010,030Unchanged
Edgewise Therapeutics Inc$150,289,7910.72%3,701,719Unchanged
Replimune Group Inc$146,240,2490.70%11,045,336Unchanged
Roivant Sciences LTD$133,859,0730.64%3,660,352-22.40%
Arrowhead Pharmaceuticals In$111,857,5190.53%1,709,053-14.24%
Nurix Therapeutics Inc$110,454,3630.53%4,658,556Unchanged
Immunovant Inc$93,583,3350.45%2,770,377-49.03%
Celldex Therapeutics Inc New$83,131,1310.40%2,564,984+116.89%
Denali Therapeutics Inc$77,188,7250.37%3,734,336Unchanged
Dianthus Therapeutics Inc$75,033,0400.36%852,164Unchanged
Rapport Therapeutics Inc$51,982,2240.25%1,547,090Unchanged
Monte Rosa Therapeutics Inc$51,844,6300.25%4,345,736Unchanged
Relay Therapeutics Inc$51,023,4330.24%2,826,783Unchanged
Ionis Pharmaceuticals Inc$45,715,5280.22%1,023,864-50.00%
Structure Therapeutics Inc$44,795,1820.21%1,432,529Unchanged
Enliven Therapeutics Inc$41,493,9550.20%905,191Unchanged
Bicycle Therapeutics PLC$40,058,1140.19%10,885,357Unchanged
Prelude Therapeutics Inc$39,584,1520.19%10,123,824Unchanged
Mirum Pharmaceuticals Inc$38,121,9430.18%445,975Unchanged
Design Therapeutics Inc$37,560,9700.18%2,988,144+11.56%
Immatics N.V$37,373,6680.18%4,256,682-55.23%
Stoke Therapeutics Inc$34,163,9740.16%1,313,999-60.62%
Entrada Therapeutics Inc$32,211,8360.15%5,072,730Unchanged
Neurogene Inc$27,588,8440.13%991,691Unchanged
Xencor Inc$27,497,5450.13%1,102,106Unchanged
Faeth Therapeutics Inc$23,893,8600.11%803,425-37.55%
Absci Corporation$22,991,8280.11%2,134,803Unchanged
Disc Medicine Inc$22,888,5470.11%349,657Unchanged
Arcus Biosciences Inc$21,821,5970.10%844,816Unchanged
Generate Biomedicines Inc$21,382,5020.10%1,423,602Unchanged
Taysha Gene Therapies Inc$19,503,1620.09%4,004,756Unchanged
Aktis Oncology Inc$19,398,9540.09%996,351Unchanged
Jade Biosciences Inc$17,287,4850.08%1,230,426Unchanged
DBV Technologies S A$17,186,3580.08%1,461,425Unchanged

Changes since Jun 30, 2026

Comparing the share counts in the two quarter-end filings: 5 new positions, 9 sold out, 7 increased, 11 reduced and 56 unchanged.

Number of positions (a count, not dollars)

  • New positions5
  • Increased7
  • Unchanged56
  • Reduced11
  • Sold out9

New positions

StockValueShares
First Tracks Biotherapeutics$16,760,710472,932
Scribe Therapeutics Inc.$12,675,358688,691
Freenome, Inc.$12,519,801794,908
Q32 Bio Inc$4,531,505547,945
Skye Bioscience, Inc.$317,017196,905

Sold out

StockValue at Jun 30, 2026Shares held then
Crinetics Pharmaceuticals In$87,991,8202,351,465
Alumis Inc$56,631,7502,012,500
Viridian Therapeutics Inc$43,776,1692,383,025
Sionna Therapeutics Inc$17,596,000400,000
Verastem Inc$9,547,4712,499,338
Sagimet Biosciences Inc$7,366,659952,996
Wave Life Sciences LTD$4,779,527822,638
Skye Bioscience Inc$1,092,1161,575,243
Surrozen Inc$13,750833,333

Largest increases

StockChange in sharesChangeValue nowShares now
Kodiak Sciences Inc+1,941,755+9.75%$2,072,417,20721,860,941
Celldex Therapeutics Inc New+1,382,373+116.89%$83,131,1312,564,984
Beone Medicines LTD+30,768+0.35%$3,232,104,6708,832,335
Design Therapeutics Inc+309,714+11.56%$37,560,9702,988,144
Evommune Inc+387,404+45.72%$10,199,3981,234,794
Protara Therapeutics Inc+872,181+89.77%$5,623,5751,843,795
Maplight Therapeutics Inc+72,648+6.64%$11,889,3151,166,763

Largest reductions

StockChange in sharesChangeValue nowShares now
Celcuity Inc-3,100,000-39.16%$382,951,7804,815,792
Revolution Medicines Inc-806,039-7.04%$2,183,415,89310,637,318
Immunovant Inc-2,664,843-49.03%$93,583,3352,770,377
Stoke Therapeutics Inc-2,022,698-60.62%$34,163,9741,313,999
Immatics N.V-5,251,883-55.23%$37,373,6684,256,682
Ionis Pharmaceuticals Inc-1,023,863-50.00%$45,715,5281,023,864
Roivant Sciences LTD-1,056,479-22.40%$133,859,0733,660,352
Arrowhead Pharmaceuticals In-283,730-14.24%$111,857,5191,709,053
Faeth Therapeutics Inc-482,986-37.55%$23,893,860803,425
Cerus Corp-4,062,276-63.52%$5,552,9092,333,155
Intellia Therapeutics Inc-101,179-10.88%$9,998,379829,053

Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.

From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures

Large ownership stakes (Schedule 13D and 13G)

CompanyFilingPercent of classSharesFiledSource
Neurogene Inc.13G amendment4.99%1,034,522Nov 16, 2026SEC.gov ↗
Stoke Therapeutics, Inc.13G amendment4.7%3,165,864Nov 16, 2026SEC.gov ↗
Revolution Medicines, Inc.13G amendment4.92%10,637,318Nov 16, 2026SEC.gov ↗
Immatics N.V.13G amendment2.8%4,256,682Nov 16, 2026SEC.gov ↗
Madrigal Pharmaceuticals, Inc.13D amendment9.99%2,330,144Nov 6, 2026SEC.gov ↗
Kodiak Sciences Inc.13D amendment35%22,049,297Sep 30, 2026SEC.gov ↗
BeOne Medicines Ltd.13D amendment7.8%115,457,154Sep 16, 2026SEC.gov ↗
IDEAYA Biosciences, Inc.13G5.2%5,010,030Aug 14, 2026SEC.gov ↗
Edgewise Therapeutics, Inc.13G amendment3.4%3,701,719Aug 14, 2026SEC.gov ↗
Cerus Corporation13G amendment3.2%6,395,431Aug 14, 2026SEC.gov ↗
Replimune Group, Inc.13D amendment11.8%11,075,336Aug 11, 2026SEC.gov ↗
Celcuity Inc.13G9.99%4,877,963Jul 16, 2026SEC.gov ↗
Kiniksa Pharmaceuticals International, plc13D amendment6.9%3,231,181May 26, 2026SEC.gov ↗
Monte Rosa Therapeutics, Inc.13G amendment9.99%8,876,346May 15, 2026SEC.gov ↗
GRAIL, Inc.13G amendment9.8%4,028,614May 15, 2026SEC.gov ↗

A firm files Schedule 13G (passive) or 13D (it may seek to influence the company) when it beneficially owns more than 5% of a class of a public company's shares. Each row is the firm's latest such filing for that company since Dec 11, 2025, exactly as filed, and counts shares held across the firm and its affiliates, not by any single fund. An amendment can report a stake that has fallen below 5%. Holdings may have changed since the filing date. Not verified by AltMountain. Showing the 15 most recent of 25 companies. Source: U.S. Securities and Exchange Commission, EDGAR.

Private investment funds filing Form D (1)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

Private funds reported on Form ADV (2)

Fund
Gross assets
Minimum
Owners
Adviser
Baker Brothers Life Sciences, L.P.
Delaware, United StatesHedge fund
Gross assets$20B
Minimum$40.0M
Owners330
AdviserBaker Brothers Investments
667, L.P.
Delaware, United StatesHedge fund
Gross assets$1.5B
Minimum$40.0M
Owners9
AdviserBaker Brothers Investments

As reported in the adviser's Form ADV filed Mar 28, 2024. Funds also listed from Form D are shown above.

From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures⁠​​‌‌‌‌‌‌‌‌​​​​​​​​​‌⁠